Ingrezza

Neurocrine Touts Phase III Huntington’s Data, Posts 29% YoY Growth
BioSpace
Fri, 11/3/23 - 11:38 am
Neurocine Biosciences
Huntington's disease
Ingrezza
Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo
Fierce Pharma
Wed, 08/23/23 - 09:48 am
Neurocrine
Ingrezza
FDA
Huntington's disease
Teva Pharmaceutical
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
New Neurocrine, Teva meds win doctors' praise, fueling bigger sales expectations
Fierce Pharma
Wed, 10/11/17 - 11:02 am
Neurocrine
Teva Pharmaceutical
physicians
Ingrezza
Austedo
tardive dyskinesia
Neurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza
Seeking Alpha
Tue, 07/11/17 - 09:36 am
Neurocrine Biosciences
Ingrezza
tardive dyskinesia
Elagolix
uterine fibroids
Hard charging Neurocrine hit with a sudden setback as Tourette study flops
Endpoints
Wed, 05/24/17 - 10:38 am
Neurocrine
Tourette's syndrome
Ingrezza
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Marketwatch
Thu, 04/27/17 - 09:14 am
Neurocrine
drug pricing
Ingrezza
tardive dyskinesia
Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug
TheStreet.com
Wed, 04/12/17 - 11:48 am
Neurocrine
tardive dyskinesia
Ingrezza
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
Neurocrine's Tourette drug misses mark in mid-stage trial
BioPharma Dive
Fri, 01/20/17 - 09:42 am
Neurocrine
Tourette's syndrome
clinical trials
Ingrezza